deltatrials
No Longer Available EXPANDED_ACCESS NCT04137822

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Sponsor: Immodulon Therapeutics Ltd

Conditions Pancreas Cancer Pancreatic Cancer Pancreatic Cancer Stage III Pancreatic Cancer Stage IV
Interventions IMM-101
Updated 5 times since 2019 Last updated: Aug 12, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Pancreas Cancer and Pancreatic Cancer and is currently ongoing. Immodulon Therapeutics Ltd leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2019 – ~Sep 2020 · 10 months · monthly snapshotAvailable~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotNo Longer Available~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotNo Longer Available~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotNo Longer Available~Sep 2024 – present · 24 months · monthly snapshotNo Longer Available

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    No Longer Available

  2. Jul 2024 — Sep 2024 [monthly]

    No Longer Available

  3. Jan 2021 — Jul 2024 [monthly]

    No Longer Available

  4. Sep 2020 — Jan 2021 [monthly]

    No Longer Available

    Status: Available → No Longer Available

  5. Nov 2019 — Sep 2020 [monthly]

    Available

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immodulon Therapeutics Ltd
  • Impatients N.V. trading as myTomorrows
Data source: Impatients N.V. trading as myTomorrows

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations